MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Price Stock Quantity  
USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MK-2206 2HCl Chemical Structure

MK-2206 2HCl Chemical Structure
Molecular Weight: 480.39

Validation & Quality Control

Cited by 174 publications:

18 customer reviews :

Quality Control & MSDS

Related Compound Libraries

MK-2206 2HCl is available in the following compound libraries:

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Product Information

  • Compare Akt Inhibitors
    Compare Akt Products
  • Research Area
  • Inhibition Profile
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Targets Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
IC50 8 nM 12 nM 65 nM
In vitro MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NCI-H292M1vBSGN6fG:2b4jpZ{BCe3OjeR?=MUizJO69VQ>?NIXrdWE4OiCqNYexepg2TE2VTx?=M4nDZmlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wNHTnSHozODV5MUC2PS=>
A431NF\DOmtMcW6jc3WgRZN{[Xl?Ml\iOUDPxE1?M3TYXFUhcA>?NHrjNpdFVVORNX31VGp[W3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKtNGrVWW0zODV5MUC2PS=>
HepG2MkXDR5l1d3SxeHnjJGF{e2G7MljMNVAh|ryPNEHze|EzPCCqM3vKTmROW09?NIrp[nVU\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI>MXuyNVIxPTl{NR?=
Sk-Hep1NUHWfpZoS3m2b4TvfIlkKEG|c3H5NFjYPIEyOCEQvF2=M3rqUFI1KGh?NHe0PINFVVORMnXTV4Vve2m2aYrld{Bz\XOrc4ThcpQh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gd49z[W[nbnniMX[yNVIxPTl{NR?=
OCUT1 cells harbored PIK3CA (H1047R+/+)NF\Ub29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX6zJO69VQ>?NWHNSWFmPSCmMU\EUXNQMlP1TWM2OD1yLkG0JO69VQ>?MWWyNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+)M{jXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnPN4J2OyEQvF2=MlHpOUBlNUnpS49zTE2VTx?=NX:yT243UUN3ME2wMlUzKM7:TR?=NUf0[m9wOjF{OEmyOlc>
FTC133 cells harbored PTEN (allele deletion and R130+)NWTCPFNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDrRotJOyEQvF2=M4O5dlUh\A>?NYr2S2k3TE2VTx?=M1jBdGlEPTB;MD6xPEDPxE1?NF\6SXkzOTJ6OUK2Oy=>
C643 cells harbored HRAS (G13R+/−)MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW[4T4xVOyEQvF2=MWe1JIQ>NFq3cIxFVVORM2LiU2lEPTB;MD6yO{DPxE1?M1;6SFIyOjh7Mk[3
Hth7 cells harbored NRAS (Q61R+/−)NIC0O|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY[zJO69VQ>?MUS1JIQ>NU\rTlJqTE2VTx?=M1vab2lEPTB;ND61JO69VQ>?MkLQNlEzQDl{Nke=
TPC1 cells harbored RET/PTC1 rearrangementNIj4ZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlvtN{DPxE1?MUm1JIQ>MV;EUXNQMn7nTWM2OD1yLkW5JO69VQ>?M1HRPVIyOjh7Mk[3
Hth74M2TOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDUN{DPxE1?MUe1JIQ>M3vZNWROW09?MnLDTWM2OD1{LkG5JO69VQ>?M2j2eVIyOjh7Mk[3
KAT18MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHQN{DPxE1?M1PUVFUh\A>?NXvjVIN1TE2VTx?=NELYXJBKSzVyPUSuOlIh|ryPNYjDWHdCOjF{OEmyOlc>
SW1736MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3kT4hCOTByIN88US=>M2fDSlUh\A>?NILue5ZFVVORNEK1TZdKSzVyPUS3MlU3KM7:TR?=MWeyNVI5QTJ4Nx?=
WROMlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVqxNFAxKM7:TR?=MkjUOUBlMVTEUXNQNVL0[ZF[UUN3ME6xNFAxKM7:TR?=NVzvcphPOjF{OEmyOlc>
TAD2M1vZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHrNVAxOCEQvF2=NYX0bZkyPSCmNGPJT4pFVVORMWLJR|UxRjFyMECg{txONUW0PIVuOjF{OEmyOlc>
LN229NWH4VWRsSXCxcITvd4l{KEG|c3H5MknJNE42KM7:TR?=MnntOlAhcA>?NF30NpBFVVORM4TxcmF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmkMXSyNlA2PzlzNB?=
T98GMV;BdI9xfG:|aYOgRZN{[Xl?NIH5OYExNjVizszNMYi2NEBpMXfEUXNQMYXBeYdu\W62czDhdI9xfG:pZX7pZ{Bm\m[nY4TzJI9nKGenZnn0bY5q[g>?M1XEblIzODV5OUG0
HC11NV\rN21MTnWwY4Tpc44hSXO|YYm=MlXTNVAh|ryPNX;KOGd5OjRiaB?=NFPEWZdFVVORM2j0S2lvcGmkaYTzJO6zNWOjc3XpckBidmRiQVTSVEB{gW62aHXzbZM>NHLDbngzOjR{Nk[yNS=>
MOLT-4MYPDfZRwfG:6aXOgRZN{[Xl?NVzSOHdlOTBizszNNELPS201QCCqM1v0TWROW09?NF\LW2VKSzVyPUGuO-KBkc7:TR?=NICwTnkzOjZzNEK0Ny=>
CEM-RMXvDfZRwfG:6aXOgRZN{[Xl?MU[xNEDPxE1?MoTROFghcA>?NX3kXZp3TE2VTx?=Mn71TWM2OD1|LkRihKnPxE1?M3rp[|IzPjF2MkSz
CEM-SNU[3WHMyS3m2b4TvfIlkKEG|c3H5MUmxNEDPxE1?NILrb2g1QCCqMXLEUXNQNVTCT4NiUUN3ME21MlHjiIoQvF2=NIrIXG4zOjZzNEK0Ny=>
MOLT-4NIL1cXdHfW6ldHnvckBCe3OjeR?=MkXDNVAh|ryPM{jJcFI1KGh?M{m1fmROW09?NXPVclI3SmyxY3vzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZTDv[kB1cGViY3XscEBkgWOuZR?=M2TncVIzPjF2MkSz
MOLT-4MkPCSpVv[3Srb36gRZN{[Xl?NEPYeZg16oDLzszNMk\IOEBpMlnlSG1UVw>?MX;JcoNz\WG|ZYOgeIhmKGGvb4XueEBw\iClbHXheoVlKEyFM1GvRkwh[SC5ZXzsMYV{fGGkbHnzbIVlKGG3dH;wbIFogSCvYYLr[ZI>M1\teVIzPjF2MkSz
CEM-RMVnGeY5kfGmxbjDBd5NigQ>?NX24eG5NPOLCid88US=>NUXyV3VGPCCqMlrmSG1UVw>?MnnBTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4VzM{HzPFIzPjF2MkSz
CEM-SMUHGeY5kfGmxbjDBd5NigQ>?MVK05qCK|ryPNUPO[IdrPCCqM1vFfmROW09?NGrvSJlKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ?Ml3NNlI3OTR{NEO=
HepG2 cellNXr1bHpMU2mwYYPlJGF{e2G7Mm[4NlAh|ryPNF7CSHUzPCCqM3L3bWROW09?M1:3VWRwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R?NWjTXGhkOjN5OUezNVk>
HepG2 cellNWfQeYZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU[zNEDPxE1?MnrFNlQhcA>?MYHEUXNQMU\Jcohq[mm2czDj[YxtKGe{b4f0bC=>M1;xVlI{Pzl5M{G5
HepG2 cellMkm0RZBweHSxc3nzJGF{e2G7NVjoeGl2OjBizszNMnXRNlQhcA>?NHXwTpdFVVORMk\VTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?NWWyVIk3OjN5OUezNVk>
GEONGHtOohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUe1NFAhdk1?MWC3NkBpNIK1R4tFVVORNG\QWIhKdmirYnn0d{Bk\WyuIHfyc5d1cA>?M1PDcVI1PThzMkOx
CNE-1NITCVlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M133OlExKM7:TR?=MWq5OkBpMoDoSG1UVw>?MXnJR|UxRTJwOU[g{txOMmXmNlU{OzZ7MkW=
CNE-2M1LDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXuxNEDPxE1?NWGyRZN3QTZiaB?=MnKwSG1UVw>?NEfM[JJKSzVyPUSuOVMh|ryPNEfL[WczPTN|NkmyOS=>
HONE-1MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vqS|ExKM7:TR?=NGfRXmU6PiCqNH\vfmtFVVORM2XBW2lEPTB;Mz6zO{DPxE1?NXT5emE4OjV|M{[5NlU>
SUNE-1MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWGxNEDPxE1?NGn3cHk6PiCqNFP2O3NFVVORNVjmdFRZUUN3ME2wMlUzKM7:TR?=NYjHOlY1OjV|M{[5NlU>
CNE-2MoXMSpVv[3Srb36gRZN{[Xl?NGfPO2UyOCEQvF2=MWC0PEBpNGfz[plFVVORMoHUTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>?MW[yOVM{Pjl{NR?=
HONE-1NIDwb2ZHfW6ldHnvckBCe3OjeR?=M2DMeVExKM7:TR?=NYTjcpVXPDhiaB?=M161fWROW09?Mon3TY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>?MUCyOVM{Pjl{NR?=
NEC8Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPKN5ZKSzVyPUCuNFk3PTFizszNM2foPXNCVkeHUh?=
P12-ICHIKAWAMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\LbVlXUUN3ME2wMlEyPjJizszNNUj1d49qW0GQR1XS
MDA-MB-175-VIIMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3XUNGlEPTB;MD6xN|c{QCEQvF2=NGDYbHZUSU6JRWK=
AsPC-1MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLxTWM2OD1yLkKyNVIzKM7:TR?=Mln6V2FPT0WU
T47DMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LMRmlEPTB;MD6yPFI2KM7:TR?=MmXxV2FPT0WU
HHMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTBwM{CyPFMh|ryPNXGzNnZ6W0GQR1XS
MOLT-16NVvGVYZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HpTWlEPTB;MD6zNFMzKM7:TR?=NIKzXmlUSU6JRWK=
ES5NW\5do9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGDpPZpKSzVyPUCuN|Q1PTVizszNNVq0eFhsW0GQR1XS
RS4-11NWnEXI1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFS2[oZKSzVyPUCuN|Q3OSEQvF2=NU\PcXRQW0GQR1XS
KARPAS-45MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlq2TWM2OD1yLkO3N|IyKM7:TR?=NVHKdnk{W0GQR1XS
NCI-H720M2f2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlP3TWM2OD1yLkO3Olc6KM7:TR?=MlWyV2FPT0WU
H9M1G4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zBRmlEPTB;MD6zPFg5OyEQvF2=Ml\BV2FPT0WU
EFM-19M1K4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHL6XWJKSzVyPUCuOFQxOSEQvF2=MUXTRW5ITVJ?
SBC-1M4\Qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTBwNESwN|Uh|ryPNG\Q[phUSU6JRWK=
A4-FukM{joO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnmTWM2OD1yLkS2PFY5KM7:TR?=MnHTV2FPT0WU
NCI-H1563MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\KZmlEPTB;MD60PFE5QSEQvF2=MV3TRW5ITVJ?
HCC1419Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnW1TWM2OD1yLkS4PFkzKM7:TR?=MVnTRW5ITVJ?
H-EMC-SSMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLvTmh[UUN3ME2wMlQ6QTN7IN88US=>NWntZlAzW0GQR1XS
BHT-101M3r0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3W1T2lEPTB;MD61Nlk3OSEQvF2=NVLITGpRW0GQR1XS
IGROV-1MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrNTWM2OD1yLkW1NlQ6KM7:TR?=Ml\MV2FPT0WU
HGC-27M3zyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTBwNU[3PFMh|ryPMmXlV2FPT0WU
MDA-MB-361Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1[zVmlEPTB;MD61O|c3OSEQvF2=MX\TRW5ITVJ?
KE-37NHTTTYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWn0WHJrUUN3ME2wMlU5OjZizszNMlXBV2FPT0WU
HCC70NIDuU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrwTWM2OD1yLkW5PFI4KM7:TR?=NIjKTW1USU6JRWK=
LNCaP-Clone-FGCNV63U5RFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvZTWM2OD1yLk[xNFQ5KM7:TR?=M{TrVXNCVkeHUh?=
HAL-01M13Qemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX6yOJRuUUN3ME2wMlYzOTNizszNNH\R[ZpUSU6JRWK=
HTM3jidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDEZZJKSzVyPUCuOlMzOzlizszNMYjTRW5ITVJ?
MDA-MB-415MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIGxN3ZKSzVyPUCuOlM3OjZizszNMlztV2FPT0WU
NOS-1M4nmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDMVVVKSzVyPUCuOlM4OjNizszNNFXJRWZUSU6JRWK=
DU-145NV;1U3lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWXJR|UxRTBwNkS3OFUh|ryPMVfTRW5ITVJ?
OCUB-MMnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYnX[Y9SUUN3ME2wMlcxQTZ4IN88US=>MWLTRW5ITVJ?
VA-ES-BJMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\5SIVtUUN3ME2wMlc{ODJ3IN88US=>NETle3JUSU6JRWK=
J-RT3-T3-5Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkT1TWM2OD1yLke0OFA{KM7:TR?=MV\TRW5ITVJ?
MOLT-4M1Xz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPwTWM2OD1yLkiwOVgzKM7:TR?=M{H6dXNCVkeHUh?=
NB7NYf0OJR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvhc25KSzVyPUCuPFI1OTFizszNNXzDOnlsW0GQR1XS
L-363NXjkZllmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPDbmJVUUN3ME2wMlg{PDR{IN88US=>NGridXZUSU6JRWK=
NKM-1NHfpXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwOE[yOVMh|ryPNXrLXXdHW0GQR1XS
HOP-92MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTBwOEeyNlMh|ryPM37sUHNCVkeHUh?=
OAW-42NF3MUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV6zcpFSUUN3ME2wMlg5PzJizszNMUDTRW5ITVJ?
HuO9M{C3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTBwOUK3OVEh|ryPNFjUWVBUSU6JRWK=
MFE-280MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\2XWxKSzVyPUCuPVY1PjVizszNM{\KVHNCVkeHUh?=
EM-2NEjrVldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk[wTWM2OD1yLkm3PVM6KM7:TR?=NGfKW|JUSU6JRWK=
NCI-H520M13wcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoriTWM2OD1yLkm4OVkzKM7:TR?=M4XSRnNCVkeHUh?=
LB2241-RCCMkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4S4dGlEPTB;MD65PVc{PCEQvF2=MX3TRW5ITVJ?
SK-NEP-1NYrofZR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfDTWM2OD1zLkG0OFg2KM7:TR?=M4rxcXNCVkeHUh?=
LXF-289MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTFwMUexOVYh|ryPNH33UHhUSU6JRWK=
EPLC-272HMorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\oUZV[UUN3ME2xMlE4OjV4IN88US=>NF3EUGZUSU6JRWK=
COLO-684NV7QTVlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{L1eWlEPTB;MT6yN|czPSEQvF2=NWLsZnUyW0GQR1XS
ES1MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTFwMkSwOlUh|ryPMlPPV2FPT0WU
DOHH-2NIraV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV\iOWRQUUN3ME2xMlI5OjB|IN88US=>NGfEcJJUSU6JRWK=
CTB-1NULzd2VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTHOJZKSzVyPUGuNlg6QSEQvF2=NYnTfnhvW0GQR1XS
G-401MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjWSVBKSzVyPUGuNlk4QTVizszNMmrFV2FPT0WU
LoVoMXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4q0bmlEPTB;MT6zNlU{PCEQvF2=NWLYTVZwW0GQR1XS
Ramos-2G6-4C10NGP3SJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3PtT2lEPTB;MT6zN|cxOSEQvF2=MljNV2FPT0WU
MFM-223M4Xad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEeye41KSzVyPUGuN|Q1PjFizszNM4PUUnNCVkeHUh?=
PA-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HBSGlEPTB;MT6zOVI3PSEQvF2=NYLlRWo6W0GQR1XS
697M3vzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULWR3l1UUN3ME2xMlM4PjF4IN88US=>MUnTRW5ITVJ?
QIMR-WILNYniW2I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fwW2lEPTB;MT60PVEyPiEQvF2=M3HZfXNCVkeHUh?=
HOSM{LWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{ftUWlEPTB;MT60PVU2QCEQvF2=NHvLTI5USU6JRWK=
DMS-273NGDIfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrtc|VzUUN3ME2xMlUyQTV7IN88US=>M1HydnNCVkeHUh?=
ME-180NVvPcmloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXW1eXlvUUN3ME2xMlU3QDlzIN88US=>M{ezdXNCVkeHUh?=
HCC2218NYTrSXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mne5TWM2OD1zLk[4NlI2KM7:TR?=M2W0RXNCVkeHUh?=
CAL-54Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\xRldKSzVyPUGuO|EzPDJizszNMXvTRW5ITVJ?
OMC-1NHLwOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\oTWM2OD1zLke0Olc4KM7:TR?=MYTTRW5ITVJ?
COR-L105NF:xflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvYTIVqUUN3ME2xMlc6PzN5IN88US=>NH;2clRUSU6JRWK=
BV-173M2HhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTFwOEGwO|Qh|ryPM1PBc3NCVkeHUh?=
RKONWDzNoNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYf0XYdwUUN3ME2xMlg4OTBzIN88US=>NVPNbnNDW0GQR1XS
SNU-387NVT3UJJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTFwOEi0NFYh|ryPM{TMdnNCVkeHUh?=
SW1088MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3HRW5KSzVyPUGuPVQ3ODZizszNNHzqWGNUSU6JRWK=
Hs-578-TNHHaZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3X4VGlEPTB;Mj6xNVQ{OyEQvF2=NF\jSIFUSU6JRWK=
OC-314NWfrW2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTJwMUWwPFYh|ryPM3u1S3NCVkeHUh?=
RMG-ING\oVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTJwMU[zPVgh|ryPMnPsV2FPT0WU
NCI-H1395NGHjVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPl[IdSUUN3ME2yMlE5ODlzIN88US=>MnTzV2FPT0WU
GAMGNIW0Wm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJwMkO4OFUh|ryPNWHwc4F6W0GQR1XS
LB1047-RCCMkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2P5Z2lEPTB;Mj6yOFMyPyEQvF2=MkXtV2FPT0WU
MN-60MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\NTWM2OD1{LkK5PVI{KM7:TR?=Ml75V2FPT0WU
OAW-28NHS0eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIn0XoVKSzVyPUKuNlk6PTFizszNNVHyNZpXW0GQR1XS
NCI-H2228M4PFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmD0TWM2OD1{LkOxOVUzKM7:TR?=M{jaWHNCVkeHUh?=
ABC-1MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{e3[2lEPTB;Mj6zN|I2OyEQvF2=Mo\LV2FPT0WU
LS-513NVzMWJZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTJwM{O0PFQh|ryPMnTaV2FPT0WU
KS-1M2\s[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGC1RotKSzVyPUKuN|gyQTFizszNNYLUNIxpW0GQR1XS
NB69M{jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PTV2lEPTB;Mj6zPFk5OyEQvF2=MUTTRW5ITVJ?
VM-CUB-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLkfVZKSzVyPUKuN|kxQDNizszNM4C0eHNCVkeHUh?=
D-423MGM2P5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPQTWM2OD1{LkSxNFQ1KM7:TR?=NWDCSHJUW0GQR1XS
EW-18M1HtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTJwNEG5N|kh|ryPMWXTRW5ITVJ?
YH-13MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoO0TWM2OD1{LkS2NVU{KM7:TR?=Mn\iV2FPT0WU
T-24M3fPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJwNEe4PFEh|ryPMn72V2FPT0WU
ES8NUTNVJRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XndWlEPTB;Mj60PVI5PyEQvF2=MVPTRW5ITVJ?
ES3MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3iTWM2OD1{LkS5O|U6KM7:TR?=NEHCWplUSU6JRWK=
RXF393NF:3b5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPHUm1KSzVyPUKuOlA1QDdizszNNGDxdYRUSU6JRWK=
RPMI-8226MnLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jxXWlEPTB;Mj62Nlk2OyEQvF2=NH61VpBUSU6JRWK=
AGSNF21d5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTJwN{KxN|ch|ryPMUfTRW5ITVJ?
HCC1395NXvsTGdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojKTWM2OD1{Lke1NVg4KM7:TR?=MkfZV2FPT0WU
MV-4-11NV3FbFFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjKSGhKSzVyPUKuO|UzPjZizszNM1zzU3NCVkeHUh?=
A204M3jrfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XRVmlEPTB;Mj64N|g4OiEQvF2=Ml3YV2FPT0WU
MCF7MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUP5U4tRUUN3ME2yMlg3OTF5IN88US=>NWn6XHRTW0GQR1XS
SNU-423NXnUdIk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXJTWM2OD1{Lki5NlQzKM7:TR?=NV;1dXJuW0GQR1XS
NCI-H1048M2SwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXftXFc5UUN3ME2yMlk3QDZ3IN88US=>M4LpNXNCVkeHUh?=
GR-STM3y2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\GR2JKSzVyPUOuNFQ3OTFizszNMnrSV2FPT0WU
EoL-1-NX;mT2JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\1TWM2OD1|LkC3NFU5KM7:TR?=NWHpeFROW0GQR1XS
HuH-7M4fVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXW1UGJwUUN3ME2zMlA6PDZ2IN88US=>MkLjV2FPT0WU
OS-RC-2NY\ZPHBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHTOXM5UUN3ME2zMlEyOTlizszNMV;TRW5ITVJ?
EW-3NV6xTZVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\3[2lEPTB;Mz6xPVUzQSEQvF2=MY\TRW5ITVJ?
NCI-H747M{i3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rsZmlEPTB;Mz6yNFY6PCEQvF2=NG\aWYxUSU6JRWK=
EW-16M1r1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV;JR|UxRTNwMkG4O|kh|ryPNFTuN|BUSU6JRWK=
DOKMlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{K5dWlEPTB;Mz6yNlg2QSEQvF2=M4XWTXNCVkeHUh?=
HCC2157M{Xxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1Xo[mlEPTB;Mz6zPFE4QSEQvF2=NYHWVGRzW0GQR1XS
OVCAR-3NYThXnRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlL2TWM2OD1|LkSwO|g3KM7:TR?=M2TWd3NCVkeHUh?=
NCI-H1623MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\0TWM2OD1|LkSxNlI1KM7:TR?=MXjTRW5ITVJ?
H4MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DWO2lEPTB;Mz60OVYzPiEQvF2=MXzTRW5ITVJ?
SW1710MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17qSWlEPTB;Mz60OlY4QCEQvF2=Mk[yV2FPT0WU
RT-112NWDWUZpDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDnVGVKSzVyPUOuOVI{QDhizszNMWfTRW5ITVJ?
DMS-114MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37reGlEPTB;Mz62NlI4QCEQvF2=NH74[ZNUSU6JRWK=
AN3-CANWe0dHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYrJR|UxRTNwNkK0OVYh|ryPMlPYV2FPT0WU
KNS-62NGHyfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf1[XBKSzVyPUOuOlM{OzhizszNNYXyZWlvW0GQR1XS
SJRH30NE\PdlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXxTWM2OD1|Lk[5NVIzKM7:TR?=M2GyZXNCVkeHUh?=
G-402M3LVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTNwN{C3NVEh|ryPMYnTRW5ITVJ?
MHH-PREB-1MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTNwN{KwN|gh|ryPM4eyT3NCVkeHUh?=
P30-OHKMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTNwOEC5O|Yh|ryPMmrYV2FPT0WU
RVH-421NILCd4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTNwOEG3PFgh|ryPM4nrWXNCVkeHUh?=
LU-134-AMnTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnO1TWM2OD1|Lki4OFI5KM7:TR?=MoXMV2FPT0WU
ECC10NEPwZWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3[1SWlEPTB;Mz65N|YzOiEQvF2=NIe1N4lUSU6JRWK=
TGWMk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVqybHJOUUN3ME20MlAzOzB3IN88US=>NUD4OWtGW0GQR1XS
MLMANVj6VVR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHXTWtKUUN3ME20MlAzQTZ4IN88US=>MorXV2FPT0WU
SCC-25MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PpRmlEPTB;ND6wOlU3PiEQvF2=NXHIZpd5W0GQR1XS
TYK-nuMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mmf5TWM2OD12LkC5OVM1KM7:TR?=NWjGZW5CW0GQR1XS
LAMA-84NIrWeGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTRwMUSxPVEh|ryPMnLPV2FPT0WU
Calu-3MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTRwMkS0NVYh|ryPNXj3cVVoW0GQR1XS
NCI-H460NYe4NGlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLXWnlKSzVyPUSuNlY1PDNizszNNVPReVRMW0GQR1XS
EGI-1NGn4[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvI[2xZUUN3ME20MlM4Pzd6IN88US=>NVfofmE3W0GQR1XS
NCI-H292M4r6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2SwWGlEPTB;ND6zPFE1PiEQvF2=MYfTRW5ITVJ?
HCE-TMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTRwNEG1O|kh|ryPMlTPV2FPT0WU
EW-11NYP5OIlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYHneoh{UUN3ME20MlQyQDN6IN88US=>Mm\EV2FPT0WU
ATN-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\nbmlEPTB;ND60OFMxPCEQvF2=MmP1V2FPT0WU
NB5M1HtU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrEcllZUUN3ME20MlU{Pjl5IN88US=>NXrMdYZvW0GQR1XS
KLEMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFjHNXJKSzVyPUSuO|AyQThizszNNFnFWolUSU6JRWK=
CAL-39NGHlfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYOwVGRJUUN3ME20MlczOTR4IN88US=>MlnkV2FPT0WU
TI-73MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojuTWM2OD12LkiwOlA6KM7:TR?=MWTTRW5ITVJ?
HO-1-N-1MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIG1OGhKSzVyPUSuPVQzKM7:TR?=Mo[wV2FPT0WU
786-0MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXy1UVN7UUN3ME20Mlk1Pjd|IN88US=>MXPTRW5ITVJ?
SK-N-DZM2fvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTRwOU[xOFIh|ryPMnTPV2FPT0WU
NCI-H446MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXMXVZKSzVyPUWuNlAxODlizszNNXjac4xmW0GQR1XS
ETK-1NWSyNVI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTVwMkGxOlUh|ryPMoL2V2FPT0WU
BT-20NHm5SWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGiycplKSzVyPUWuNlE{PTNizszNMkDsV2FPT0WU
MEL-HONV3vdnc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M16xe2lEPTB;NT6zO|M{PiEQvF2=M{i3NnNCVkeHUh?=
CAL-27M{npXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTVwNE[zN|kh|ryPM{\OcHNCVkeHUh?=
SW872MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PMUGlEPTB;NT61PVQzQCEQvF2=M3f1eXNCVkeHUh?=
RPMI-2650M{PJ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mo\pTWM2OD13Lk[2NVk6KM7:TR?=NY[3OmQ6W0GQR1XS
PFSK-1NGHFOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTTTWM2OD13LkeyO|MzKM7:TR?=NXjodmZNW0GQR1XS
SF295MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2myZ2lEPTB;NT64NFY{OyEQvF2=NWLOb3JbW0GQR1XS
BeckerNXTES404T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTVwOE[0O|Ih|ryPNXfWbGluW0GQR1XS
Saos-2MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmK4TWM2OD13Lki2OVMh|ryPNFvzTnZUSU6JRWK=
SK-OV-3MmS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTVwOUm4NVYh|ryPM{f5dHNCVkeHUh?=
VMRC-RCZMkPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LQUWlEPTB;Nj6wPFc4OyEQvF2=Ml3DV2FPT0WU
EW-22M1;Nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWmxbYE1UUN3ME22MlE6PjR7IN88US=>NELyNphUSU6JRWK=
BT-474NWDvZWRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFy4clBKSzVyPU[uNlM{KM7:TR?=NW\uS496W0GQR1XS
BFTC-909MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3n1[2lEPTB;Nj6zNFM1PSEQvF2=NFfCTZlUSU6JRWK=
NB12NWXKd4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTZwM{mwO|Eh|ryPM4mxWXNCVkeHUh?=
D-263MGNVrQXottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\6N2lEPTB;Nj60OVE3QSEQvF2=MljWV2FPT0WU
SNB75NFjtfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4[5NmlEPTB;Nj62NFE1OyEQvF2=MW\TRW5ITVJ?
A704NVm2U5VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fzfGlEPTB;Nj62N|A3KM7:TR?=Mkm3V2FPT0WU
NCI-H1693M1jjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnpOHNKSzVyPU[uOlM3ODRizszNMYXTRW5ITVJ?
LN-405NX\xUlA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfnPI1LUUN3ME22Mlc6Pjd{IN88US=>NH7hb49USU6JRWK=
CHL-1NFPWS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTZwOECwO|kh|ryPNEDFSnVUSU6JRWK=
A498NHvnS5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnWTWM2OD14LkixPVYyKM7:TR?=MmjhV2FPT0WU
TE-12M1K5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTZwOEO4NVch|ryPNIj0V21USU6JRWK=
TE-6NYrxdYl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTZwOUOwN|gh|ryPNULQNJhPW0GQR1XS
AU565NGey[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{H4[GlEPTB;Nj65Olk2PyEQvF2=MY\TRW5ITVJ?
RDMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnITJpKSzVyPU[uPVgzQDRizszNNV\6ZVdJW0GQR1XS
SW1463M2PKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV:zV5RrUUN3ME23MlEyOTZ6IN88US=>NGjafJZUSU6JRWK=
LU-99ANIXXUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGn0NIdKSzVyPUeuNVQ{OjJizszNMX7TRW5ITVJ?
NCI-H28MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fxO2lEPTB;Nz6yPVI1KM7:TR?=MVTTRW5ITVJ?
MC-IXCM13yPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGjaTG9KSzVyPUeuOFg2PzZizszNMX3TRW5ITVJ?
GP5dMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3f5SmlEPTB;Nz60PFc3PCEQvF2=NXzT[4VHW0GQR1XS
GB-1NVjSN4RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTdwNUS4NFQh|ryPMWTTRW5ITVJ?
CAL-33NVO0Wmt1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWe3XXJvUUN3ME23MlY3OjN|IN88US=>MVvTRW5ITVJ?
MSTO-211HMlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFXPOmhKSzVyPUeuOlc{OzZizszNMVvTRW5ITVJ?
TE-5NGHyWpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTdwN{mzN|Qh|ryPNHnWTWRUSU6JRWK=
D-566MGMYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvlfZhKSzVyPUiuNFQ1OjlizszNMl:2V2FPT0WU
JVM-3Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHrYd|FKSzVyPUiuNVUzPjhizszNMlLvV2FPT0WU
T98GMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkC4TWM2OD16LkG4NFY4KM7:TR?=NGTIb4ZUSU6JRWK=
HCC1954MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXSWWZ3UUN3ME24MlQ2OTB2IN88US=>NV;mWYxzW0GQR1XS
SF126MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRThwNEW5N|Yh|ryPMXnTRW5ITVJ?
LB996-RCCNEfKWnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HVTWlEPTB;OD61N|I2PyEQvF2=MmPiV2FPT0WU
SKG-IIIaNU\wZnlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTj[mZKSzVyPUiuOlMxPjlizszNNVvLTGtVW0GQR1XS
NCI-SNU-1NHnGc3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRThwNkS2OFMh|ryPMVrTRW5ITVJ?
LB771-HNCMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRThwNkS2PVYh|ryPM4DBfHNCVkeHUh?=
SCC-4M{e0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPzTWM2OD16Lk[4NlE6KM7:TR?=MVTTRW5ITVJ?
CAMA-1MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUjQfJF7UUN3ME24Mlc4OTR4IN88US=>MYPTRW5ITVJ?
D-502MGM{X6[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF32TYhKSzVyPUiuO|g3OjlizszNMonWV2FPT0WU
ESS-1MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRThwOEi3NFQh|ryPNGrobXNUSU6JRWK=
HEC-1M{XuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVm4R5h2UUN3ME24Mlg6QDZ4IN88US=>M2XoPHNCVkeHUh?=
NB10MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk[4TWM2OD17LkCyNlI1KM7:TR?=Mn7VV2FPT0WU
8505CNF25emVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEjCRYFKSzVyPUmuNFQzOzJizszNMmrnV2FPT0WU
EFO-27MlHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXSVGFKSzVyPUmuNVY1OTJizszNNU[xXJZwW0GQR1XS
HNMlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3hTWM2OD17LkG2OlI5KM7:TR?=MUPTRW5ITVJ?
DSH1Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MY\JR|UxRTlwMkC4O{DPxE1?NGTNUW1USU6JRWK=
NBsusSRM{\KVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlT5TWM2OD17LkK3OFAzKM7:TR?=M3u3XXNCVkeHUh?=
LS-123M1jUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTlwM{G3OlEh|ryPNV3CWmFzW0GQR1XS
SHP-77MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTlwM{m5N|Uh|ryPNITrWIdUSU6JRWK=
ACNMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTlwNUOyO|ch|ryPNWjS[mptW0GQR1XS
U251M4XxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7vN4VKSzVyPUmuOlU2PDRizszNNWjrTVZ1W0GQR1XS
A431MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfjcoVNUUN3ME25MlgxOjN6IN88US=>M{PHcHNCVkeHUh?=
5637NEnkOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTlwOES5PFQh|ryPM3zwcnNCVkeHUh?=
MDA-MB-157NXLVZYFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLSdJZKSzVyPUmuPVI5PzhizszNMVjTRW5ITVJ?
A101DMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTlwOUm5O|Qh|ryPM4S2XHNCVkeHUh?=
YKG-1NYXxSW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYKzdI9mUUN3ME2xNE4zODB4IN88US=>NYm4N|V2W0GQR1XS
LAN-6NEHoSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnO3TWM2OD1zMD6yNVY1KM7:TR?=NEH2VHJUSU6JRWK=
OVCAR-5M3[0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLpPW9KSzVyPUGwMlI1OzNizszNNYGyc3JzW0GQR1XS
A549MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3W2eWlEPTB;MUCuN|k4OyEQvF2=M13WbnNCVkeHUh?=
no-11NHy1eWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PoNWlEPTB;MUCuOFM2OyEQvF2=MWjTRW5ITVJ?
SF539MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PHWGlEPTB;MUCuPVA1OSEQvF2=Ml[5V2FPT0WU
A388Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVexdlcyUUN3ME2xNU4{QDl5IN88US=>NXf4dVN3W0GQR1XS
DELMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkX0TWM2OD1zMT60NlQh|ryPNH7ybWlUSU6JRWK=
SW954NYrCXFVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XnZmlEPTB;MUGuOFY3QCEQvF2=MVPTRW5ITVJ?
TK10MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4Xuc2lEPTB;MUGuOVI4OSEQvF2=NVnDdVREW0GQR1XS
SW756NELRZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWO3NG1XUUN3ME2xNU42Ojl2IN88US=>MkWxV2FPT0WU
PC-3M3LrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVH6cnpUUUN3ME2xNU42PzZ2IN88US=>MnzoV2FPT0WU
ONS-76MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLS[WxuUUN3ME2xNU43OzZizszNNEX6eIlUSU6JRWK=
A427NEWzS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTFzLkewPVMh|ryPNVfHOnZ7W0GQR1XS
MEG-01MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPiTWM2OD1zMT63OVA6KM7:TR?=M2fvbXNCVkeHUh?=
BB30-HNCNVzH[XhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnXV2NKSzVyPUGxMlc6QDJizszNM3XyOXNCVkeHUh?=
NCI-H1299MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTFzLkiwPVMh|ryPNFLuTW9USU6JRWK=
GCTM2rW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTFzLkiyNlgh|ryPM33EPHNCVkeHUh?=
D-247MGMnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGP2VJFKSzVyPUGxMlk3PjNizszNM1LafnNCVkeHUh?=
CFPAC-1MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLYTWM2OD1zMT65O|gzKM7:TR?=MlHRV2FPT0WU
EKVXNUnMRXk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mor3TWM2OD1zMj6wN|E{KM7:TR?=NXu1U445W0GQR1XS
CAL-51M4HnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHUTWM2OD1zMj6wO|E3KM7:TR?=MUHTRW5ITVJ?
BB49-HNCMlnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTF{LkGxO|ch|ryPMWrTRW5ITVJ?
RPMI-7951MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DFeWlEPTB;MUKuNVg2PCEQvF2=MVLTRW5ITVJ?
RH-1M3q0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NY\2cpVJUUN3ME2xNk4zOTh2IN88US=>M3rHbHNCVkeHUh?=
BCPAPNEDqNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq1TWM2OD1zMj60O|Q6KM7:TR?=M1S3[XNCVkeHUh?=
GCIYMmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETpOVlKSzVyPUGyMlUzODlizszNMmrDV2FPT0WU
KNS-81-FDNEXxZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1z5R2lEPTB;MUKuOVg3QSEQvF2=NXfRfW12W0GQR1XS
KYSE-140M4PWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPiXnZRUUN3ME2xNk45PTl3IN88US=>MYLTRW5ITVJ?
Ca-SkiMk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PUNWlEPTB;MUKuPVA1OSEQvF2=NGjQcm1USU6JRWK=
TGBC1TKBNHf4WmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPUTWM2OD1zMj65NVE2KM7:TR?=M{njc3NCVkeHUh?=
HCC1187MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXftVId7UUN3ME2xN{4yQTF{IN88US=>NYLuPWVYW0GQR1XS
SJSA-1MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvLVmxSUUN3ME2xN{4zOzJ5IN88US=>MkfFV2FPT0WU
CTV-1M1nlSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETle2lKSzVyPUGzMlM1PSEQvF2=NXPMN4ZZW0GQR1XS
WM-115NV3Yd|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XaV2lEPTB;MUOuOlQ5OyEQvF2=MXPTRW5ITVJ?
CHP-212NGHtbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmL0TWM2OD1zMz65O|M6KM7:TR?=NXPueZBHW0GQR1XS
SCC-15MmLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDlemZKSzVyPUGzMlk4PzVizszNM2jWdnNCVkeHUh?=
BPH-1MoT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vLbWlEPTB;MUSuNVY3PCEQvF2=M3ziXXNCVkeHUh?=
SW780M{TpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TnRmlEPTB;MUSuOVAzPSEQvF2=M1T5[HNCVkeHUh?=
NCI-H2291MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTF2LkW4O|gh|ryPMULTRW5ITVJ?
JEG-3MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvMNIpKSzVyPUG0MlY{OjZizszNMofhV2FPT0WU
CAL-120NVH1RoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3oNGQ3UUN3ME2xOE44ODJ5IN88US=>M{jkV3NCVkeHUh?=
NCI-H23MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXf3NWtxUUN3ME2xOE44QTl5IN88US=>MXvTRW5ITVJ?
MS-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\yOFRKSzVyPUG0Mlk3OTFizszNNXLJTHU6W0GQR1XS
PC-14NWP2TotQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfqTJVFUUN3ME2xOE46PjV2IN88US=>M33rNXNCVkeHUh?=
D-283MEDMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHPTWhmUUN3ME2xOU4xOTFzIN88US=>NHjGN|NUSU6JRWK=
OE19NF;Re4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTF3LkG1OFEh|ryPNV7pZYFpW0GQR1XS
CAS-1NWPvNnd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYP5XmNyUUN3ME2xOU41OTh2IN88US=>MVTTRW5ITVJ?
NCI-H727NFnwR4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk\aTWM2OD1zNT60NlIyKM7:TR?=NFKzOWpUSU6JRWK=
SiHaMn[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVe5V|RbUUN3ME2xOU44PTl2IN88US=>NV3BfpJ[W0GQR1XS
BFTC-905NEXXVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTF3Lke2PVQh|ryPNVzUc2FNW0GQR1XS
MDA-MB-453MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTF4LkG2OFIh|ryPM1LQTHNCVkeHUh?=
HuP-T3M4GwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\GTWM2OD1zNj62N|c{KM7:TR?=NHz5NW9USU6JRWK=
SK-LU-1NYHWW2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPsT4Z7UUN3ME2xOk43QTV4IN88US=>M1vmWHNCVkeHUh?=
Detroit562NFLHbVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nhVmlEPTB;MU[uO|MyQCEQvF2=NGD0S2pUSU6JRWK=
HCC1569MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTF4LkizN|ch|ryPNFX2WpZUSU6JRWK=
SK-MES-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjOTWM2OD1zNj64OFE6KM7:TR?=M4nSVXNCVkeHUh?=
BB65-RCCMlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPDRVNKSzVyPUG3MlA1PzlizszNNV:4cGFqW0GQR1XS
LOXIMVINVj5SIU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4r0SWlEPTB;MUeuNFcxPyEQvF2=MVTTRW5ITVJ?
SW1783Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LXdGlEPTB;MUeuNVI5KM7:TR?=NGPUWphUSU6JRWK=
NH-12M1XYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGnNOoVKSzVyPUG3MlM{ODNizszNM3XsdXNCVkeHUh?=
UACC-257NFvLNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NITWTmtKSzVyPUG3MlU2OTJizszNM2POcXNCVkeHUh?=
KOSC-2M{j5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWftdFE3UUN3ME2xO{43PzV5IN88US=>NULCSHEyW0GQR1XS
KG-1MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWS1R5c6UUN3ME2xO{43QTN5IN88US=>NIfvRmJUSU6JRWK=
M059JM3TKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{G2UmlEPTB;MUeuO|A{KM7:TR?=Mo[wV2FPT0WU
MHH-NB-11NEiwT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHscpplUUN3ME2xO{46Pjd|IN88US=>NWn1S5R4W0GQR1XS
EW-1NFrUT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTF6LkGzPFIh|ryPNHfNO5dUSU6JRWK=
CAL-85-1NVzZTWgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfuTWM2OD1zOD6yN|U4KM7:TR?=MnXwV2FPT0WU
639-VMoDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofjTWM2OD1zOD6zN|U1KM7:TR?=M3rrdnNCVkeHUh?=
C32M2\rO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTnTWM2OD1zOD60O|I4KM7:TR?=Ml\GV2FPT0WU
KM-H2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rvdmlEPTB;MUiuOVI{OiEQvF2=MVXTRW5ITVJ?
A253NHnLXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHIXGdKSzVyPUG4MlczQDZizszNNYPqeFlnW0GQR1XS
NCI-N87NXz2V|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zoVGlEPTB;MUiuPVAxQCEQvF2=NU\hO2ZbW0GQR1XS
8-MG-BAMn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHezWYhKSzVyPUG5MlA3PDZizszNMWTTRW5ITVJ?
GI-ME-NMlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVjJR|UxRTF7LkG1OFYh|ryPM3rPWHNCVkeHUh?=
8305CNH3XdnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFH0WpNKSzVyPUG5MlIzQDZizszNMnTuV2FPT0WU
TE-8NFXodVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTF7LkOwNlQh|ryPM3LGNHNCVkeHUh?=
KYSE-270MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTJyLkCyNVch|ryPNVvmRlQ5W0GQR1XS
HL-60NELDZY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPyTWM2OD1{MD6wPVQyKM7:TR?=MUnTRW5ITVJ?
Mo-TNITPRY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTWNXE5UUN3ME2yNE4yPjZ3IN88US=>MljjV2FPT0WU
NCI-H1355MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjXcoc6UUN3ME2yNE4{Ozd2IN88US=>NFXEdoNUSU6JRWK=
HT-1080Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjnXZZKSzVyPUKwMlU1QTdizszNMknCV2FPT0WU
MIA-PaCa-2Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn7vTWM2OD1{MD62PFg{KM7:TR?=NX;FVYJEW0GQR1XS
NCI-H441M1zF[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWT3SHpYUUN3ME2yNE44Ozd7IN88US=>MkLUV2FPT0WU
LCLC-97TM1NVKzO2s1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXrVldKSzVyPUKwMlgyOzRizszNMUDTRW5ITVJ?
HT-3M3LRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWm5W21SUUN3ME2yNU42PjNzIN88US=>MljJV2FPT0WU
22RV1NGjXZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTJzLkW2PFUh|ryPNH3w[ItUSU6JRWK=
LK-2MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nYZWlEPTB;MkGuOVk2OyEQvF2=M{nrXXNCVkeHUh?=
CW-2NILueXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4S3PWlEPTB;MkGuOlA3QSEQvF2=MmT2V2FPT0WU
KYSE-510NH3Fb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnrhTWM2OD1{MT62NFk2KM7:TR?=NEnvOYxUSU6JRWK=
CGTH-W-1NV3Udm5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTnUldxUUN3ME2yNU44OTZ4IN88US=>NITXTYpUSU6JRWK=
NCI-H661NX7TWZptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3DTWM2OD1{Mj6wN|Qh|ryPM{S5RXNCVkeHUh?=
KU-19-19M{PiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnv4TWM2OD1{Mj6xOlk4KM7:TR?=NUXHOIZkW0GQR1XS
NCI-H2122M3e1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrVPXZ2UUN3ME2yNk4zPDN{IN88US=>M2DOZnNCVkeHUh?=
NCI-H526NFHsXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX3JR|UxRTJ{LkO4PVUh|ryPM{PwdXNCVkeHUh?=
NCI-H1650NHvBdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH73dmlKSzVyPUKyMlc3PCEQvF2=M4fudHNCVkeHUh?=
AM-38NGTBeJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXkdYhKSzVyPUKyMlg3QDlizszNMUPTRW5ITVJ?
NCI-H2405M3HCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF;CNohKSzVyPUKzMlI2OzNizszNMUHTRW5ITVJ?
M14Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILVcHVKSzVyPUKzMlQxQDhizszNMlHPV2FPT0WU
ES4MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPoWoN2UUN3ME2yN{41OjN{IN88US=>NVrobIlRW0GQR1XS
DJM-1NVrT[45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jwN2lEPTB;MkOuOVI{PCEQvF2=M1j6WXNCVkeHUh?=
S-117M1LHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfnVIdKSzVyPUKzMlc3PTFizszNMonKV2FPT0WU
MZ2-MELM2rvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTJ|Lke3OVkh|ryPNGrGbGRUSU6JRWK=
SK-MEL-2NHTKTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3P6ZmlEPTB;MkOuPFE{OyEQvF2=MknjV2FPT0WU
HCC1806M4XwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfDbIhKSzVyPUKzMlg4ODlizszNMoHGV2FPT0WU
NMC-G1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUjJUGw1UUN3ME2yOE4zOjJ4IN88US=>MXjTRW5ITVJ?
DK-MGNEnaO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYTBSJJYUUN3ME2yOE4zQTRizszNMXzTRW5ITVJ?
SK-N-FINXzYPGhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXKxV|NKUUN3ME2yOE4{OzB{IN88US=>M2nne3NCVkeHUh?=
KINGS-1NHi5SY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jPV2lEPTB;MkSuOFg4PCEQvF2=NXL0e3R3W0GQR1XS
HCC2998NGnU[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDtVHFKSzVyPUK0MlQ5QDVizszNNFnENJBUSU6JRWK=
ALL-POM{jBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojzTWM2OD1{ND62NVkh|ryPMm\1V2FPT0WU
MPP-89MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTJ3LkC0OVgh|ryPNWDSd3A4W0GQR1XS
NCI-H2342NWjLXWQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVi4S|lMUUN3ME2yOU4yQTV|IN88US=>NX3ibXk{W0GQR1XS
TE-1MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHoe2pKSzVyPUK1MlM2PjNizszNM2\wb3NCVkeHUh?=
RH-18M174Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4i4[mlEPTB;MkWuOVkyQCEQvF2=MnGxV2FPT0WU
HT-1376NWTDenFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFy3N4hKSzVyPUK1MlY1PjVizszNMUHTRW5ITVJ?
U-2-OSMoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MULJR|UxRTJ3Lk[4PFgh|ryPMXLTRW5ITVJ?
BT-549NXTBSnYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3P0cmlEPTB;MkWuPVAyOSEQvF2=M1LF[3NCVkeHUh?=
NCI-H1755M{XRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnf1TWM2OD1{NT65PVQ2KM7:TR?=MWHTRW5ITVJ?
EW-13MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXVTWM2OD1{Nj6wNlc1KM7:TR?=Mn3UV2FPT0WU
NB13NVfLcmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MliyTWM2OD1{Nj6wPVQ6KM7:TR?=NGfPT41USU6JRWK=
NUGC-3MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRTJ4LkKxNFMh|ryPMVzTRW5ITVJ?
GMS-10NI\PNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml;JTWM2OD1{Nj6yN|U{KM7:TR?=MYXTRW5ITVJ?
CHP-134MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTpbnA6UUN3ME2yOk4{QDZ5IN88US=>NEjqdW1USU6JRWK=
SW962MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7yXlNHUUN3ME2yOk42ODJzIN88US=>M3;iZ3NCVkeHUh?=
SNU-449MkDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4H2c2lEPTB;MkeuNFgxOyEQvF2=NV;wUolsW0GQR1XS
HuP-T4NUDTT2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlixTWM2OD1{Nz6wPFc6KM7:TR?=NVzGN2s3W0GQR1XS
SW948MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXlUJFzUUN3ME2yO{4yOzR2IN88US=>MVHTRW5ITVJ?
NCI-H226M3rLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3u4bmlEPTB;MkeuOFU4QCEQvF2=NF3VRXJUSU6JRWK=
SK-PN-DWNEDUephIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlzETWM2OD1{Nz62NFEzKM7:TR?=MYDTRW5ITVJ?
GI-1MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTJ5LkeyNUDPxE1?MY\TRW5ITVJ?
CAL-12TMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTJ6LkGxNVIh|ryPMYfTRW5ITVJ?
YAPCNV7VWJd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\I[YRKSzVyPUK4MlI2PjRizszNMWjTRW5ITVJ?
SNU-C2BM1fibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTJ6LkK5OlQh|ryPMV\TRW5ITVJ?
RCC10RGBNWDOdplRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoHGTWM2OD1{OD61OFE4KM7:TR?=NVrJSZJTW0GQR1XS
ES7M2D1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3rnVGlEPTB;MkmuNVQ3PSEQvF2=MnHYV2FPT0WU
PANC-03-27MnPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nvPGlEPTB;MkmuOFQ1KM7:TR?=M4nNdnNCVkeHUh?=
ES6NHrOO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTJ7LkixOVch|ryPNVjDS4dNW0GQR1XS
HT-1197MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnhZ5pKSzVyPUOwMlA2QThizszNM4DqZXNCVkeHUh?=
ZR-75-30MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTNyLkKzPFMh|ryPNWDqVm9PW0GQR1XS
DBMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTNyLkS5OFIh|ryPMlHSV2FPT0WU
OCI-AML2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTBVWc5UUN3ME2zNU4xPjlizszNMVvTRW5ITVJ?
NCI-H2170MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPWTWM2OD1|MT64OVE3KM7:TR?=NIjGeodUSU6JRWK=
IST-MES1M2jkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zCO2lEPTB;M{KuNlg6PyEQvF2=M4nLdHNCVkeHUh?=
769-PMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nvOGlEPTB;M{KuN|Y1OSEQvF2=MX3TRW5ITVJ?
COR-L23M4PZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmf1TWM2OD1|Mj65NFc{KM7:TR?=MlrtV2FPT0WU
SW626M3LEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\3c5loUUN3ME2zN{4yPzd4IN88US=>M2XDVXNCVkeHUh?=
LU-139MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFXNUGNKSzVyPUOzMlY3ODVizszNNG\lSGxUSU6JRWK=
HT-144NFTFNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\4U2lEPTB;M{OuPFY{KM7:TR?=NHrzXlRUSU6JRWK=
CaR-1NEXXUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1T2VGlEPTB;M{OuPVgzOiEQvF2=NYrEWZRuW0GQR1XS
OE33M2rxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX\SU5VlUUN3ME2zOE4zQDV3IN88US=>NIHD[4tUSU6JRWK=
COLO-800NULMW5Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLVTWM2OD1|ND6zOlQ4KM7:TR?=NHzU[mNUSU6JRWK=
NB14NUTYXlhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jTdmlEPTB;M{SuOFY5PCEQvF2=NHvzNlBUSU6JRWK=
KURAMOCHIM1f6SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2jvcWlEPTB;M{[uNVE6QCEQvF2=MWLTRW5ITVJ?
SW48MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml7hTWM2OD1|Nj6yOFc1KM7:TR?=M4qxNHNCVkeHUh?=
DaoyNUW5dmc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlTiTWM2OD1|Nj62OVM5KM7:TR?=MonBV2FPT0WU
TGBC24TKBNEjuUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTN4Lk[3JO69VQ>?NXeySpZSW0GQR1XS
DU-4475MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjDWXZpUUN3ME2zOk46ODN|IN88US=>Mln5V2FPT0WU
SW1417NHrPUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEHvdnRKSzVyPUO4MlA2PTJizszNNIfTfFRUSU6JRWK=
EFO-21MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUO2N292UUN3ME2zPE46OzR7IN88US=>M3uxV3NCVkeHUh?=
MG-63M{jjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HERWlEPTB;M{muN|QzPCEQvF2=MnrFV2FPT0WU
LC-2-adM4ez[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;lcJlIUUN3ME2zPU42PTF{IN88US=>NWLWSYh2W0GQR1XS
NOMO-1NUfJUZEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXnyXnp6UUN3ME2zPU45Ojd2IN88US=>MYDTRW5ITVJ?
COLO-741MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInySFNKSzVyPUSwMlE{ODRizszNNWHaRYNNW0GQR1XS
BxPC-3Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnnbIJKSzVyPUSwMlU3QDZizszNNWTVeIRvW0GQR1XS
HSC-2NWG1cpIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoL6TWM2OD12MD65NVE{KM7:TR?=NIPicnlUSU6JRWK=
UMC-11NX;yblJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLZTWM2OD12MT6yOlMh|ryPNH;L[oRUSU6JRWK=
HCC1937NYLHdldIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\XcGlEPTB;NEKuO|g1OyEQvF2=M1r0VnNCVkeHUh?=
Calu-6MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnmxTWM2OD12Mz6yN|gzKM7:TR?=NUfrTGRNW0GQR1XS
NCI-H1573NV;OXnk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTD[YZ2UUN3ME20N{4{PDd5IN88US=>NFm5bZJUSU6JRWK=
SK-N-ASMof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfzcoVKSzVyPUSzMlYxOTlizszNMlnFV2FPT0WU
PSN1M{PkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYrJR|UxRTR3LkK1OFgh|ryPMVHTRW5ITVJ?
TE-11NVf6Wo56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYrDN2FTUUN3ME20OU41QDR{IN88US=>MnrVV2FPT0WU
NCI-H1155MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrVeW1mUUN3ME20OU45QTZ5IN88US=>MYDTRW5ITVJ?
KM12M1rUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2TzNmlEPTB;NEWuPVA4PiEQvF2=NHXlVItUSU6JRWK=
RO82-W-1NYnCTWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Xw[2lEPTB;NE[uPVgzOiEQvF2=MVLTRW5ITVJ?
SW1573NIXITHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzqXWtKSzVyPUS3MlM4OzZizszNM1nS[XNCVkeHUh?=
CAKI-1NVjPe2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX3JR|UxRTR6LkK4OFUh|ryPM3SyeHNCVkeHUh?=
U-118-MGM374fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHMTWM2OD12OD6zO|AzKM7:TR?=MYDTRW5ITVJ?
KYSE-520MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTR6LkSwNVYh|ryPNIn4NGpUSU6JRWK=
HT55MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPuTWM2OD12OT6xOFc1KM7:TR?=MoH4V2FPT0WU
ChaGo-K-1M4TyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DKfGlEPTB;NEmuOFc6OyEQvF2=MlH1V2FPT0WU
IA-LMMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkO0TWM2OD13ND62N|IzKM7:TR?=MlzxV2FPT0WU
UACC-62MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TTXWlEPTB;NUWuNVA1PiEQvF2=NHLYNIRUSU6JRWK=
MKN7M3OxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX64V4dPUUN3ME21Ok4xOjh3IN88US=>NYG5V2hFW0GQR1XS
HPAF-IINUnwUIhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2Lt[GlEPTB;NU[uOFA4OyEQvF2=NFu3SW9USU6JRWK=
NTERA-S-cl-D1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPDOHh2UUN3ME21O{44PzhizszNMXzTRW5ITVJ?
FTC-133NIHv[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXzXnBKSzVyPUW4MlA6PjlizszNMnHUV2FPT0WU
MHH-ES-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\3R|ZtUUN3ME21PE41QDF2IN88US=>MWjTRW5ITVJ?
JVM-2M3XsUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTV6Lkm1NFYh|ryPMUDTRW5ITVJ?
TCCSUPM{jmV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7jUHZKSzVyPUW5MlUzPzlizszNMnTEV2FPT0WU
COLO-824NFz3WHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWnJR|UxRTZyLkC3NVkh|ryPMoCzV2FPT0WU
647-VNEPGW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnBW40{UUN3ME22NE4yOzR5IN88US=>NFjhTW5USU6JRWK=
HD-MY-ZMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFfwbGNKSzVyPU[wMlUzQTRizszNMX3TRW5ITVJ?
LS-411NNIPDXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYX4TldbUUN3ME22NU4{QTB|IN88US=>MUfTRW5ITVJ?
NCI-H596MkHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTZ{Lke0PVYh|ryPNFvKUFFUSU6JRWK=
C-33-ANX;4NVFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDiTWM2OD14ND6wPVU4KM7:TR?=NGnDXppUSU6JRWK=
BHYMkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTZ2LkGyOFUh|ryPMlX5V2FPT0WU
KGNM2DIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHtdIxiUUN3ME22OE42PTF2IN88US=>NWrGTWV{W0GQR1XS
NCI-H1092NXrUZZVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3wdnNkUUN3ME22OU4xODl3IN88US=>NUC5fGd4W0GQR1XS
MZ1-PCMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jJeWlEPTB;NkWuOVY1QSEQvF2=M2fEPXNCVkeHUh?=
LB831-BLCNIewSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mm\MTWM2OD14NT64OFgyKM7:TR?=MWrTRW5ITVJ?
SW620MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fKS2lEPTB;Nk[uNlA{QSEQvF2=MWLTRW5ITVJ?
HuO-3N1NUXVXWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4KxWWlEPTB;NkiuN|I{QCEQvF2=MYDTRW5ITVJ?
SK-HEP-1NI\RcldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXznNoZ4UUN3ME22PU46PDh4IN88US=>Mn3YV2FPT0WU
LCLC-103HM4fpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3MTo1sUUN3ME23NE43PzB3IN88US=>NGPxOndUSU6JRWK=
KYSE-70MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mk\oTWM2OD15MD63PFM2KM7:TR?=NGPhXpdUSU6JRWK=
MewoMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3lRngyUUN3ME23NU42ODVizszNMYjTRW5ITVJ?
COLO-668NVK2NlJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLGOmI2UUN3ME23NU45PDVzIN88US=>NH;ySoVUSU6JRWK=
NCI-H522MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrZ[mVKSzVyPUeyMlM1OTNizszNNFe3WHNUSU6JRWK=
NCI-H1437NFvMeFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rzU2lEPTB;N{SuOFA1QCEQvF2=NFjzSHNUSU6JRWK=
U-266MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTXN5J6UUN3ME23OU41PTF4IN88US=>NFXLeZlUSU6JRWK=
MC116MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXrW3EzUUN3ME23OU42PzB6IN88US=>MWPTRW5ITVJ?
PANC-10-05Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DtOmlEPTB;N{euOFI1OyEQvF2=NHWwXmNUSU6JRWK=
KYSE-180MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;6WYYzUUN3ME23O{42PDV2IN88US=>NXnESGlLW0GQR1XS
JARMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVOwdoVzUUN3ME23PU4xPTR4IN88US=>M3HEOHNCVkeHUh?=
CAL-62Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1zPT2lEPTB;OECuNFk2KM7:TR?=NXTBXIdEW0GQR1XS
A3-KAWMnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXRbmc2UUN3ME24NE4zOTV2IN88US=>M1PnTXNCVkeHUh?=
PANC-08-13M365SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DrbWlEPTB;OEGuNVc3QCEQvF2=NYPYTIFYW0GQR1XS
HSC-3MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\UTWM2OD16Mz6zNFcyKM7:TR?=MVnTRW5ITVJ?
HTC-C3MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTh|LkS3NFIh|ryPM{Wx[XNCVkeHUh?=
KY821MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDLblhKSzVyPUi0MlA5QTJizszNNILyRphUSU6JRWK=
DoTc2-4510MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mle3TWM2OD16ND6yNVg2KM7:TR?=NGDP[JlUSU6JRWK=
NCI-H1581NF;R[ZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXjTWM2OD16NT60OlQyKM7:TR?=MV7TRW5ITVJ?
KARPAS-299NV\TSHA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjiTHVQUUN3ME24Ok4yQTd5IN88US=>MXrTRW5ITVJ?
IST-MEL1NV\Oenp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHixO2dKSzVyPUi2Mlg5PzJizszNMmnIV2FPT0WU
KP-N-YSMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX\JR|UxRTh7LkmwNlgh|ryPNIjV[m9USU6JRWK=
KYSE-410MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTlzLkSwOFIh|ryPNG\NS|hUSU6JRWK=
TE-10NV[zVZJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTWd|lKSzVyPUmxMlU3OTFizszNNHj6[VNUSU6JRWK=
SK-MEL-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFuw[G9KSzVyPUmyMlkyODZizszNMVjTRW5ITVJ?
COLO-792MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTl3LkK1OlQh|ryPMn\lV2FPT0WU
SCHMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTl4LkO4O|ch|ryPMkLrV2FPT0WU
NCI-H1792NUDxT|Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV74bm1vUUN3ME25Ok45QTl{IN88US=>M4LQ[nNCVkeHUh?=
NCI-H2029NWfGNYc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1T4WWlEPTB;OU[uPVU3PiEQvF2=MXTTRW5ITVJ?
SW684MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELBbo5KSzVyPUm4MlY3PTRizszNNETUWJZUSU6JRWK=
NCI-H209MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIW1eodKSzVyPUGwNE4yOjFizszNMWfTRW5ITVJ?
HLEM1nF[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HSdWlEPTB;MUC1MlI5OiEQvF2=NFPl[mZUSU6JRWK=
GOTONWnGdYp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnP3TWM2OD1zMEeuO|c4KM7:TR?=MljDV2FPT0WU
NCI-H1793M1XGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXLKSWVVUUN3ME2xNFkvOjhizszNNV36PYJIW0GQR1XS
D-392MGNVvKc4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTFzNz6zPVgh|ryPMW\TRW5ITVJ?
SW1990NEXzUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LZUmlEPTB;MUKwMlk2OSEQvF2=MnP6V2FPT0WU
ML-2NEj3c25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnq[WZMUUN3ME2xNlEvPjd4IN88US=>MYTTRW5ITVJ?
NCI-H2452NYDQRopZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvNTWM2OD1zMkKuNlEh|ryPNV\wSVVtW0GQR1XS
SK-MEL-30MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[3WW1KSzVyPUGyN{4zPDRizszNNWfSW2x{W0GQR1XS
SN12CMnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVriOWNVUUN3ME2xNlQvOTd4IN88US=>MkGyV2FPT0WU
NCI-H1770M1[xPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHn6XJRKSzVyPUGyOU42OTRizszNMVvTRW5ITVJ?
SF268Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjZOpg1UUN3ME2xNlYvOTV6IN88US=>MXvTRW5ITVJ?
BALL-1NWLZNI5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTF{Nj6yN{DPxE1?MkjJV2FPT0WU
COLO-679MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4f0c2lEPTB;MUK2Mlc2OyEQvF2=MmHmV2FPT0WU
A2780M4DsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\4foNKSzVyPUGyPE46QDhizszNM2mxOXNCVkeHUh?=
NCI-H1651MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTZVFBKSzVyPUGzNU4zPDNizszNNGLmV4xUSU6JRWK=
NCI-H2087NW\aR4w5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELyb4RKSzVyPUGzNU41QDNizszNMmrGV2FPT0WU
U-87-MGNFXufYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTF|Mz62NFQh|ryPMmPJV2FPT0WU
LB2518-MELMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7qZVBxUUN3ME2xN|UvQTl|IN88US=>M3;kTXNCVkeHUh?=
HCT-116NFfLNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NELO[XBKSzVyPUGzO{4zOTdizszNNHrJOopUSU6JRWK=
Ca9-22MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTF|OT64N|Mh|ryPNIHrVWpUSU6JRWK=
COR-L88MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHK4WmhKSzVyPUG0Nk4yPCEQvF2=M2Syd3NCVkeHUh?=
CP50-MEL-BMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTF2ND61NFEh|ryPNIHWNm9USU6JRWK=
OVCAR-8NHfqdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDXTlJKSzVyPUG0OU43OzZizszNMVTTRW5ITVJ?
SK-MEL-3NEHGVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3MWphKSzVyPUG0O{45PzhizszNM2jYfHNCVkeHUh?=
GT3TKBNWXwdIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWLE[ZB{UUN3ME2xOFkvQTJ6IN88US=>Ml;FV2FPT0WU
KYSE-450NGnMfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPvZYRKUUN3ME2xOVEvPTN7IN88US=>M17MfHNCVkeHUh?=
CAPAN-1M1XwPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF3Mz6wOlQh|ryPMVjTRW5ITVJ?
BENM1L5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFnseFhKSzVyPUG1N{46OjhizszNMXzTRW5ITVJ?
NCI-H1304NFrJN4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\3TWM2OD1zNUSuOlk1KM7:TR?=MnrLV2FPT0WU
KU812MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnYb|ZQUUN3ME2xOVgvPjd2IN88US=>MmjiV2FPT0WU
Capan-2NW\EZY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3i5emlEPTB;MU[wMlU2OyEQvF2=Ml3pV2FPT0WU
A673MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXH2O2JHUUN3ME2xOlEvPzB3IN88US=>M1HnTnNCVkeHUh?=
SASM4DyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPOZYxKSzVyPUG2Nk43PzhizszNM3K0eHNCVkeHUh?=
NYMorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjJWlNDUUN3ME2xOlUvOzF2IN88US=>MYPTRW5ITVJ?
HCE-4NGLSSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fNRWlEPTB;MU[2Mlg1PSEQvF2=MoPNV2FPT0WU
MDA-MB-231NWLocIJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n6VWlEPTB;MUe3MlUxOyEQvF2=MVTTRW5ITVJ?
no-10NWr0[XJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;HV2lEPTB;MUe4MlE{PCEQvF2=MV;TRW5ITVJ?
MZ7-melMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PBR2lEPTB;MUe4MlQ3PyEQvF2=NITPRW1USU6JRWK=
NCI-H82Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHKyXphKSzVyPUG4NE4yPjVizszNNGqzSFhUSU6JRWK=
CAL-72M4rpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfERXhKSzVyPUG4OU4xPTRizszNMo\ZV2FPT0WU
NCI-SNU-5M2jkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHjTWM2OD1zOE[uPFQh|ryPNFj0[3NUSU6JRWK=
OVCAR-4MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnztTWM2OD1zOEiuN|M{KM7:TR?=MofMV2FPT0WU
SCC-9M{LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTF7MTFOwG0>NXfL[4FrW0GQR1XS
KYSE-150Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGS3VZBKSzVyPUG5NU45QDhizszNM4OwPHNCVkeHUh?=
HT-29NVvuUFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7xVIxKSzVyPUKwNU4zOTJizszNM{DHSXNCVkeHUh?=
COLO-678MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV7IT5JtUUN3ME2yNFEvPDVizszNMUDTRW5ITVJ?
NCI-H650MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTJyMj6xNFMh|ryPMn\MV2FPT0WU
HuCCT1M3rkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXoTWM2OD1{MESuNlA5KM7:TR?=MYPTRW5ITVJ?
SW1116M3XnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFv3bnBKSzVyPUKwO{4xPzdizszNMke5V2FPT0WU
DBTRG-05MGM3LTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PKbWlEPTB;MkC3MlkxQSEQvF2=MWrTRW5ITVJ?
SW982M1vnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPrTWM2OD1{MEeuPVQ5KM7:TR?=MmrVV2FPT0WU
RCM-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITmXm5KSzVyPUKxOE44PjJizszNMWLTRW5ITVJ?
COLO-320-HSRMkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjPNWVKSzVyPUKxOk4yOjVizszNNG\5N2RUSU6JRWK=
KNS-42MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITkSWFKSzVyPUKxOk42PzRizszNM3vYT3NCVkeHUh?=
C2BBe1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkjITWM2OD1{M{GuPVA2KM7:TR?=NUDi[2R4W0GQR1XS
CCRF-CEMMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MluwTWM2OD1{NEOuO|k2KM7:TR?=Mk\uV2FPT0WU
SH-4NH;6d|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF3ZfFRKSzVyPUK0Ok4xQSEQvF2=M1vQdnNCVkeHUh?=
LS-1034MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnUTWM2OD1{NE[uNlY3KM7:TR?=MnTWV2FPT0WU
NCI-H2347NXHGb3lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXWTWM2OD1{NEeuO|E{KM7:TR?=NV7JOnB1W0GQR1XS
RPMI-8866NXu3SmJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TufWlEPTB;MkS5MlI4KM7:TR?=MXzTRW5ITVJ?
GAKNEjpTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1juVmlEPTB;MkWzMlAxOiEQvF2=MWPTRW5ITVJ?
NB6NGTNVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknDTWM2OD1{N{CuNUDPxE1?Mly5V2FPT0WU
COLO-680NMnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWXJR|UxRTJ5Mj61Nlch|ryPMofDV2FPT0WU
RERF-LC-MSNH;IS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfMcVFKSzVyPUK3Ok4xODdizszNMXPTRW5ITVJ?
TGBC11TKBNXTiR5RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TsR2lEPTB;Mke4MlE4QCEQvF2=Mmj4V2FPT0WU
C8166M{Tk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPWTWM2OD1{N{iuOVA3KM7:TR?=M2rtPXNCVkeHUh?=
HDLM-2NEjtWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{P1T2lEPTB;Mkm0MlQxQSEQvF2=NV\6dVgxW0GQR1XS
IGR-1NITiPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkH5TWM2OD1{OUWuOlU6KM7:TR?=NHvDRWpUSU6JRWK=
FADUNFHLTllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnCPG82UUN3ME2yPVcvPTFizszNMlXaV2FPT0WU
L-428MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTJ7Nz62NVYh|ryPMkHKV2FPT0WU
LU-65MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1faeWlEPTB;M{C0MlMzKM7:TR?=NUDUOpAxW0GQR1XS
HELNFn3WVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTNyOT65PFMh|ryPNYDOZo1SW0GQR1XS
NCI-H810MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTNzMD61O{DPxE1?MmC1V2FPT0WU
C3AMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkXMTWM2OD1|MUGuPFAzKM7:TR?=MofnV2FPT0WU
NCI-H630M4jwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHuNIZKSzVyPUOzNk4zQTRizszNM1XnUXNCVkeHUh?=
KP-N-YNMoTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnPlTWM2OD1|NEGuNVI{KM7:TR?=M3HR[nNCVkeHUh?=
MOLT-13MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoLqTWM2OD1|NEKuN|I3KM7:TR?=NXXTXohmW0GQR1XS
NCI-H1993NXTJZ5hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\JTWM2OD1|NEKuN|Y2KM7:TR?=Ml34V2FPT0WU
BE-13Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIS5dmNKSzVyPUO0OE4yPjdizszNNGPuXYpUSU6JRWK=
IST-SL1NXq4[oVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPjZ|BKSzVyPUO0O{41ODFizszNNFfQ[m9USU6JRWK=
TE-9MlPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLXTmxGUUN3ME2zOlMvPTh7IN88US=>NEPZZ29USU6JRWK=
LU-135M{PORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTN4Nz6wN|Uh|ryPM{fie3NCVkeHUh?=
T84M4TMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoT3TWM2OD1|N{SuO|EzKM7:TR?=NWnHbmNPW0GQR1XS
K-562MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPoTWM2OD1|OEOuN|Yh|ryPMnnyV2FPT0WU
SBC-5MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGC0PGZKSzVyPUO4Ok46QDVizszNNXv5TFJ2W0GQR1XS
NB17M1fvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojxTWM2OD1|OUKuOVk3KM7:TR?=MV3TRW5ITVJ?
NCI-H2052MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljwTWM2OD1|OUiuOFczKM7:TR?=MV\TRW5ITVJ?
HCC38Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXXJR|UxRTRyMT61PVMh|ryPMWnTRW5ITVJ?
NCI-H69Ml\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\UTWM2OD12NEGuNFg{KM7:TR?=NWKzNWhyW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.

Protocol(Only for Reference)

Kinase Assay: [4]

Akt kinases assay Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.

Cell Assay: [2]

Cell lines A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
Concentrations 0, 0.3, 1 and 3 μM
Incubation Time 72 or 96 hours
Method MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.

Animal Study: [2]

Animal Models SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
Formulation Formulated in 30% Captisol
Dosages 120 mg/kg
Administration Orally administered

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Yan L, AACR Annual Meeting 2009: Abstract Number: DDT01-1.

[2] Hirai H, et al. Mol Cancer Therapy, 2010, 9(7), 1956-1967.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-06-25)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent  ...more Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|St  ...more Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adu  ...more Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|  ...more Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

view more

Chemical Information

Download MK-2206 2HCl SDF
Molecular Weight (MW) 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 15% Captisol 17 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

Customer Product Validation(18)


Click to enlarge
Rating
Source Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines Ser78 cells
Concentrations 5 µM
Incubation Time 1 h
Results Two selective AKT inhibitors MK-2206 and GDC-0068, both significantly reduced MKK4 phosphorylation on Ser78 in axons after injury.

Click to enlarge
Rating
Source Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck
Method analysis of luciferase activity
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results In this experiment, animalstreated with dexamethasone or MK2206 showed progressivetumor growth similar to that observed in vehicle-treated controls,while mice treated with MK2206 plus dexamethasone had significant antitumor responses.

Click to enlarge
Rating
Source Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines PC9GR4/WZR10 cells
Concentrations 1 uM
Incubation Time 72 h
Results The addition of a dual PI3K and MTOR inhibitor, PI103, or the AKT inhibitor MK-2206, did reduce the expression of pAKT neither in GR4 cells nor WZR10 cells.

Click to enlarge
Rating
Source J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck
Method 3D migration model
Cell Lines WT or Rap1b-/- neutrophil
Concentrations 2 uM
Incubation Time
Results MK-2206 treatment completely reversed elevated TEM across mouse endothelial cells of Rap1b-/- neutrophils to WT levels (A). It reduced ECM degradation of Rap1b -/- neutrophils, and inhibited their multiple protrusions (B and C). Furthermore, almost all Rap1b -/- cells treated with MK-2206 were found at the endothelial cell junctions (D).

Click to enlarge
Rating
Source Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck
Method Western Blot
Cell Lines HUVECs
Concentrations 1 uM
Incubation Time 8 h
Results Because YAP is also a known substrate of Akt21, we examined whether blockade of the Akt pathway affects YAP phosphorylation. Both Ly294002, an inhibitor of phosphoinositide 3-kinase (PI3K), and MK-2206, an allosteric inhibitor of Akt, suppressed cell contact-mediated YAP phosphorylation.

Click to enlarge
Rating
Source Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck
Method Immunoblotting
Cell Lines CXCR4S338X-expressing BCWM.1 cells
Concentrations 0.5 uM
Incubation Time 6 h
Results As AKT and ERK, but not BTK, show continued SDF-1a-triggered activation in CXCR4S338X-expressing WM cells treated with ibrutinib, we next sought to clarify if AKT and ERK contributed to the enhanced survival of these cells. It therefore treated SDF-1acultured CXCR4S338X BCWM.1 cells with either AKT- (MK-2206 and AZD-5363) or MEK- (AS-703026, AZD-6244 and UO126) specific inhibitors with and without ibrutinib (0.5 uM) for 6 h so as to clarify the contribution of AKT and ERK to ibrutinib resistance. The inhibitory activity of MK-2206, as well as AS-703026, AZD-6244 and UO126 was confirmed by western blot analysis for pAKT (S473) and pERK (T202/Y204), respectively.

Click to enlarge
Rating
Source Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines SKNAS/SJNB8/IMR32/GIMEN/SHEP2/KCNR/NGP/LAN1/LAN5/TR14/UHGNP cell lines
Concentrations 8 μM
Incubation Time 48 h
Results The 8 μM MK-2206 treatments resulted in effective pathway inhibition in all cell lines as shown by western blot for phosphoryl ated FOXO3a and PRAS40 as well as AKT serine 473 phosphorylation.

Click to enlarge
Rating
Source Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck
Method Western blot/ Wst-1 assay
Cell Lines ATC/ FTC cell lines
Concentrations 500 nM
Incubation Time 1 h/72 h
Results One-hour treatment with the AKT inhibitor MK-2206 (0.5 μM) or with the MEK inhibitor U0126 (10 μM) effectively abolished AKT and ERK1/2 phosphorylation in all cell lines.

Click to enlarge
Rating
Source Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck
Method ELISA
Cell Lines HeLa cells
Concentrations 1 μM
Incubation Time
Results Treatment of infected cells with kinase inhibitors directed at Akt (MK-2206), MEK(PD 98059), PKC(CEC), or Pim family kinases identified a dominant role for Pim family kinases in the release of IL-8 from Salmonella-infected epithelial cells.

Click to enlarge
Rating
Source FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck
Method Clonogenic growth assay
Cell Lines U2OS cells
Concentrations 1 μM
Incubation Time 9 d
Results Specific inhibition of PKB activity using MK-2206 or triciribine also significantly reduced cell growth, although to a lesser extent compared to PI-103, suggesting that both the PKB and mTOR pathways are important for anchorage-dependent growth.

Click to enlarge
Rating
Source Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines ovarian cancer cell lines
Concentrations 1-6 μM
Incubation Time 1 h/72 h
Results Activation of pAKT by IGF-1 in the low-grade cell line HOC-7 was blocked by the AKT inhibitor MK-2206.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Confocal microscopy
Cell Lines platelets
Concentrations 1μM
Incubation Time
Results Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines platelets
Concentrations 1 μM
Incubation Time
Results eNOSser1177 phosphorylation was greatly reduced by LY294002 and cancelled by MK2206 but it was not modified by platelet pretreatment with EGTA or BAPTA/AM.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Nitriter+Nitrate(NOX) measurement, cGMP detection
Cell Lines platelets
Concentrations 1 μM
Incubation Time 1 min
Results As shown in Figure 4 SR1 significantly reduced both NOx and cGMP formation, while SR2 failed to affect these parameters.

Click to enlarge
Rating
Source Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck
Method Western blot, clonogenic survival assay
Cell Lines U87MG cells
Concentrations 1 μM
Incubation Time 1 h
Results Akt inhibitor MK-2206 showed similar effect. MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. U87MG cells were preincubated with 1 μM MK-2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As shown in Fig C, MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MGcells (Fig. D)

Click to enlarge
Rating
Source Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck
Method Immunofluorescence
Cell Lines HC11 cells
Concentrations 10 µM
Incubation Time 1 h
Results whole ADRP levels, estimated by Western blot , decreased only in the presence of MK -2206 and LY294002. In most cases, ADRP decorated the surface of small lipid droplets and appeared as little patches on large cytoplasmic lipid droplets. With the exception of SP600125, which induced a strong ADRP coating of almost all cytoplasmic lipid droplets (although this inhibitor did not increase ADRP synthesis), variation in the distribution of ADRP at the surface of lipid droplet was difficult to estimate, notably because the signal was faint and uneven.

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results Breast cancer cells were serum starved for 24 h, pretreated with the indicated concentrations of MK-2206 for 3 h, and then treated with 100ng/ml EGF for 15 min.

Click to enlarge
Rating
Source MK-2206 2HCl purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/100 nM/250 nM/1000 nM
Incubation Time 24 h
Results The effect of MK-2206 on the serine 473 phosphorylation mark of AKT 1 was uneven and did not correlate with inhibition of AKT activity, but the AKT1 mutant cells maintained higher levels of AKT1 serine 473 phosphorylation with increasing concentrations of MK-2206. Of note, MK-2206 completely inhibited AKT2 activation at 100 nM, a concentration where PIK3CA E545K mutant, but not AKT1 mutant cells were already strongly growth inhibited. MK-2206 treatment up to 1 μM did not have strong effects on other protein biomarkers such as ribosomal protein S6, ev en though growth was suppressed by approximately 80% in MCF-7 cells at this concentration.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Akt Products

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • SC79

    SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.

  • Honokiol

    Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Phase 3.

Recently Viewed Items

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us